OptimizeRx (OPRX) Competitors

OptimizeRx (NASDAQ:OPRX) and Accolade (NASDAQ:ACCD) are both small-cap computer and technology companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, community ranking, profitability, valuation and dividends.

Do analysts recommend OPRX or ACCD?

OptimizeRx presently has a consensus target price of $9.06, suggesting a potential downside of 0.63%. Accolade has a consensus target price of $6.51, suggesting a potential downside of 7.31%. Given OptimizeRx's stronger consensus rating and higher possible upside, equities research analysts clearly believe OptimizeRx is more favorable than Accolade.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OptimizeRx	0 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.78
Accolade	0 Sell rating(s)	13 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.07

Which has more risk and volatility, OPRX or ACCD?

OptimizeRx has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500. Comparatively, Accolade has a beta of 2.1, meaning that its share price is 110% more volatile than the S&P 500.

Which has stronger earnings & valuation, OPRX or ACCD?

OptimizeRx has higher earnings, but lower revenue than Accolade. OptimizeRx is trading at a lower price-to-earnings ratio than Accolade, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OptimizeRx	$92.13M	1.83	-$17.57M	-$1.10	-8.29
Accolade	$446.72M	1.29	-$99.81M	-$2.25	-3.12

Is OPRX or ACCD more profitable?

OptimizeRx has a net margin of -27.41% compared to Accolade's net margin of -40.36%. OptimizeRx's return on equity of -4.92% beat Accolade's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OptimizeRx	-27.41%	-4.92%	-3.41%
Accolade	-40.36%	-20.74%	-11.33%

Does the MarketBeat Community prefer OPRX or ACCD?

OptimizeRx received 55 more outperform votes than Accolade when rated by MarketBeat users. Likewise, 64.08% of users gave OptimizeRx an outperform vote while only 55.14% of users gave Accolade an outperform vote.

Company	Underperform	Outperform
OptimizeRx	Outperform Votes 157 64.08%	Underperform Votes 88 35.92%
Accolade	Outperform Votes 102 55.14%	Underperform Votes 83 44.86%

Does the media prefer OPRX or ACCD?

In the previous week, OptimizeRx had 1 more articles in the media than Accolade. MarketBeat recorded 3 mentions for OptimizeRx and 2 mentions for Accolade. OptimizeRx's average media sentiment score of 1.78 beat Accolade's score of 0.00 indicating that OptimizeRx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OptimizeRx	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Accolade	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do insiders & institutionals believe in OPRX or ACCD?

76.5% of OptimizeRx shares are owned by institutional investors. Comparatively, 85.0% of Accolade shares are owned by institutional investors. 6.1% of OptimizeRx shares are owned by insiders. Comparatively, 8.2% of Accolade shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

OptimizeRx beats Accolade on 14 of the 19 factors compared between the two stocks.